Download Neurofibromatosis

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Neurofibromatosis
By Shannon Weeks
What is Neurofibromatosis?
• Neurofibromatosis type I (NF1) is caused by mutation in the
neurofibromin gene
• AKA von Recklinghausen disease , Watson disease
• An autosomal dominant neurogenetic disorder
• Characterized by the presence of multiple benign neurofibromas
• Affects the bone, the nervous system, soft tissue, and the skin
• Clinical symptoms increase over time
• Neurologic problems and malignancy may develop
Neurofibromatosis-1
• NF-1 occurs in approximately 1 of 2500-3300 live births
• This disease can involve various body systems over time
• Signs can range from benign cutaneous manifestations to
extreme disfigurement
• The mortality rate is higher than that of the healthy population
because of the increased potential for malignant transformation
of diseased tissues and the development of neurofibrosarcoma
• Patients with NF-1 have about a 3-15% additional risk of
malignant disease in their lifetime
• All racial groups are affected equally
• Women and men are affected equally
Genotype/Phenotype…ect
•
Increased concentrations of nerve growth stimulating activity have
been linked with the development of neurofibromatosis
•
NF-1 is a disorder with variable phenotypic expression
•
Some patients may mainly have cutaneous expression, and others may
have life-threatening or sever disfigurement
•
The variation of this disease is even shown within families
•
The spontaneous mutation rate is 100 times greater than for many
genes, and it is thought to contribute to approximately 30-50% of
neurofibromatosis cases.
•
A genotype- phenotype analysis suggests that there is no clear
relationship between specific NF1 mutations and clinical features of
Neurofibromatosis type 1.
Diagnostic criteria for NF-1
•
(The diagnostic criteria are met if 2
or more of the features listed are
present.)
–
–
–
–
–
–
–
Six or more café au lait macules
larger than 5 mm in greatest
diameter in prepubertal individuals
and those larger than 15 mm in
greatest diameter in postpubertal
individuals
Two or more neurofibromas of any
type or 1 plexiform neurofibroma
Freckling in the axillary or inguinal
regions
Optic glioma
Two or more Lisch nodules (iris
hamartomas)
A distinctive osseous lesion, such as
sphenoid dysplasia or thinning of
the long bone cortex, with or
without pseudoarthrosis
A first-degree relative with NF-1
according to the above criteria
More Clinical Features of NF-1
•
•
•
•
•
•
•
•
•
•
•
•
Scoliosis
Pseudarthrosis of the tibia
Pheochromocytoma
Meningioma
Glioma
Acoustic neuroma
Optic neuroma
Mental retardation
Hypertension
Hypoglycemia
Fibromas in Iris
Glaucoma - rare
Neurofibromas
•
Most common benign tumor of NF-1
•
These tumors are made yp ofof Schwann
cells, fibroblasts, mast cells, and vascular
components
•
They can form at any place along a nerve
•
Three subtypes of neurofibroma exist:
cutaneous, subcutaneous, and plexiform
•
Cutaneous lesions and subcutaneous
lesions are circumscribed. These
nodules may be brown, pink, or skin
colored. They may be soft or firm to the
touch
•
Plexiform neurofibromas are
noncircumscribed, thick, and irregular,
and they can cause disfigurement by
entwining important supportive structures
•
Cellular loss of wild type NF1 allele is
associated with neurofibromas
Protein Function/Biochemistry
•
Neurofibromin is a cytoplasmic protein that is expressed in neurons, Schwann cells,
oligodendrocytes, astrocytes and leukocytes
•
It is encoded by the gene NF1
•
It is located on chromosome 17, at the band q11.2
•
It has several biochemical functions, including association to microtubules and participation
in several signaling pathways
•
Alterations in the protein are responsible for a phacomatosis named neurofibromatosis type
1
•
Neurofibromin has a guanosine triphosphatase (GTPase) region that binds to Ras and
positively modulates conversion of guanosine triphosphate (GTP) to guanosine diphosphate
(GDP)
•
The protein is necessary for the negative regulation of Ras protein signal; telling us that
neurofibromin acts as a tumor suppressor
•
Needed for the negative regulation through the cell cycle
3-D Visualization
Ball and Stick
Analysis of mutations
•
Many different mutations in the neurofibromatosis gene have been described.
•
In 95% of NF1 individuals, a mutation is found in the NF1 gene
•
5% of the patients, the germline mutation consists of a microdeletion that
includes the NF1 gene and several other genes
•
45 mutations within the NF1 gene are associated with neurofibromatosis type 1
•
Mutations are found in exon 2
•
Mutations in this exon involves an insertion of cytosine into codon 5662 and
resulted in an early stop codon.
•
Another mutation in exon 2 is from the insertion of the amino acid thymidine at
nucleotide 5678, which also creates an early stop codon.
•
Mutations in NF1 can also lead to juvenile myelomonocytic leukemia
References
• http://www.ncbi.nlm.nih.gov/entrez/vie
wer.fcgi?db=nucleotide&val=109826563
• http://www.ncbi.nlm.nih.gov/Structure/
mmdb/mmdbsrv.cgi?form=6&db=t&Do
pt=s&uid=38151
• http://www.ncbi.nlm.nih.gov/entrez/dis
pomim.cgi?id=162200